Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oral BPM31510 in Healthy Subjects
NCT03002935Phase 1Completed
- Sponsor
- BPGbio
- Start
- Jan 2017
- Primary completion
- Mar 2017
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BPM31510-Oral in solid tumor, sponsored by BPGbio. Primary endpoints: Maximum Plasma Concentration at Day 15 and Area Under the Plasma Concentration Curve at Day 15. Started Jan 2017; status: completed.
02
Drugs
BPM31510-Oral
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03002935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002935.